Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Target Price at $42.60

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have received an average rating of “Moderate Buy” from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $42.60.

A number of analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. HC Wainwright increased their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Piper Sandler restated a “neutral” rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, Truist Financial boosted their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the transaction, the executive vice president now owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. This trade represents a 15.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. The trade was a 13.81 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds have recently made changes to their positions in COLL. Gladius Capital Management LP purchased a new position in Collegium Pharmaceutical in the second quarter valued at $32,000. GAMMA Investing LLC boosted its stake in shares of Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 792 shares during the period. CWM LLC grew its position in shares of Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after buying an additional 736 shares in the last quarter. nVerses Capital LLC increased its stake in shares of Collegium Pharmaceutical by 1,600.0% during the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 1,600 shares during the period. Finally, TD Private Client Wealth LLC raised its holdings in Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after acquiring an additional 483 shares in the last quarter.

Collegium Pharmaceutical Trading Up 1.3 %

COLL stock opened at $31.19 on Friday. Collegium Pharmaceutical has a 12-month low of $25.16 and a 12-month high of $42.29. The business’s 50-day moving average is $35.56 and its 200 day moving average is $34.68. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of 13.27 and a beta of 0.95.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.